Challenges Before Considering Full-Dose Anticoagulation in Noncritically Ill Patients With COVID-19

Basit Öğe Kaydı
dc.authorid0000-0002-4873-4391
dc.contributor.authorAğırbaşlı, Mehmet
dc.date.accessioned2025-05-10T19:50:01Z
dc.date.issued2023
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstract[No abstract available]
dc.identifier.doi10.1016/j.jacc.2023.05.053
dc.identifier.endpage1
dc.identifier.issn0735-1097
dc.identifier.issn1558-3597
dc.identifier.issue7
dc.identifier.pmid37558379
dc.identifier.scopusqualityQ1
dc.identifier.startpage1
dc.identifier.urihttps://doi.org/10.1016/j.jacc.2023.05.053
dc.identifier.urihttps://hdl.handle.net/20.500.14730/12211
dc.identifier.volume82
dc.identifier.wosWOS:001054774800001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.institutionauthorAğırbaşlı, Mehmet
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofJournal of The American College of Cardiology
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.titleChallenges Before Considering Full-Dose Anticoagulation in Noncritically Ill Patients With COVID-19
dc.typeLetter

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
12211.pdf
Boyut:
60.44 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu